Serum levels and clinical significance of IFN-γ and IL-10 in PATIENTS with coronary heart disease

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 7, 2016, Pages 1339-1343

  Liang, K ^a   Dong, S R ^a   Peng, H ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Atherosclerosis; Coronary heart disease; Interferon ; Interleukin 10

Indexed keywords

CHOLESTEROL; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; IFNG PROTEIN, HUMAN; IL10 PROTEIN, HUMAN;

AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY OBSTRUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED;

AGED; BIOMARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 85017130932     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. ESMON CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013;109:416-420.
2. ANOGEIANAKI A, ANGELUCCI D, CIANCHETTI E, D'ALESSANDRO M, MACCAURO G, SAGGINI A, SALINI V, CARAFFA A, TETE S, CONTI F, TRIPODI D, SHAIK-DASTHAGIRISAHEB YB. Atherosclerosis: a classic inflammatory disease. Int J Immunopathol Pharmacol 2011;24:817-825.
3. HAN X, KITAMOTO S, WANG H, BOISVERT WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010;24:2869-2880.
4. LITTLE PJ, CHAIT A, BOBIK A. Cellular and cytokinebased inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther 2011;131:255-268.
5. TUTTOLOMONDO A, DI RAIMONDO D, PECORARO R, ARNAO V, PINTO A, LICATA G. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012;18:4266-4288.
6. WEBER C, HRISTOV M. Atherogenesis and inflammation. From cellular mediators to regulatory mechanisms of inf lammat ion in atherosclerosis. Hamostaseologie 2015;35:99-101.
7. CHARO IF, TAUB R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011;10:365-376.
8. LIBBY P, RIDKER PM, HANSSON GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325.
9. MOORE KJ, TABAS I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-355.
10. BILLIAU A, MATTHYS P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009;20:97-113.
11. NIEDZIELSKA I, CIERPKA S. Interferon gamma in the etiology of atherosclerosis and periodontitis. Thromb Res 2010;126:324-327.
12. FOTEINOS G, XU Q. Immune-mediated mechanisms of endothelial damage in atherosclerosis. Autoimmunity 2009;42:627-633.
13. VOLOSHYNA I, LITTLEFIELD MJ, REISS AB. Atherosclerosis and interferon-gamma: new insights and therapeutic targets. Trends Cardiovasc Med 2014;24:45-51.
14. HAN X, BOISVERT WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage funct ion. Thromb Haemost 2015;113:505-512.
15. HAN X, KITAMOTO S, LIAN Q, BOISVERT WA. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem 2009;284:32950-32958.